Press Releases

Press Releases

    Date Title View
    09/16/20
    Summary ToggleMIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
    PDF Version
    09/02/20
    Summary ToggleHorizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List
    PDF Version
    09/01/20
    Summary ToggleHorizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
    PDF Version
    08/11/20
    Summary ToggleHorizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
    PDF Version
    08/10/20
    Summary ToggleHorizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business
    PDF Version
    08/06/20
    Summary ToggleHorizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares
    PDF Version
    08/06/20
    Summary ToggleHorizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
    PDF Version
    08/05/20
    Summary ToggleHorizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
    PDF Version
    08/05/20
    Summary ToggleHorizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‐Year 2020 Net Sales and Adjusted EBITDA Guidance
    07/31/20
    Summary ToggleNew Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
    PDF Version
    Displaying 1 - 10 of 43 results